Scarica l'app Stockscreener
62.07
2.53%
+1.53
Precedente Chiudi:
$60.54
Aprire:
$62.48
Volume 24 ore:
1.61M
Capitalizzazione di mercato:
$11.41B
Reddito:
$2.50B
Utile/perdita netta:
$-204.15M
Rapporto P/E:
-39.14
EPS:
-1.5857
Flusso di cassa netto:
$31.93M
1 W Prestazione:
+5.47%
1M Prestazione:
-14.76%
6M Prestazione:
-7.39%
1 anno Prestazione:
-2.54%
Intervallo 1D:
$61.47
$63.99
Portata 52W:
$56.05
$100.77
Exact Sciences Corp. Stock (EXAS) Company Profile
Nome
Exact Sciences Corp.
Settore
Industria
Telefono
608-284-5700
Indirizzo
441 Charmany Drive, Madison, WI
Exact Sciences Corp. Stock (EXAS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-01-02 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2023-12-14 | Iniziato | Guggenheim | Buy |
| 2023-12-13 | Iniziato | Wolfe Research | Outperform |
| 2023-10-10 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2023-09-28 | Iniziato | Bernstein | Outperform |
| 2023-08-02 | Downgrade | The Benchmark Company | Buy → Hold |
| 2023-05-10 | Aggiornamento | Craig Hallum | Hold → Buy |
| 2023-05-05 | Iniziato | UBS | Neutral |
| 2023-03-09 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-02-10 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2023-01-18 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2022-10-19 | Downgrade | Craig Hallum | Buy → Hold |
| 2022-08-25 | Iniziato | Credit Suisse | Outperform |
| 2022-06-03 | Iniziato | Piper Sandler | Neutral |
| 2021-11-03 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2021-07-29 | Reiterato | BTIG Research | Buy |
| 2021-07-29 | Reiterato | Canaccord Genuity | Buy |
| 2021-07-29 | Reiterato | Oppenheimer | Outperform |
| 2021-07-29 | Reiterato | Stifel | Buy |
| 2021-06-15 | Iniziato | Raymond James | Strong Buy |
| 2021-06-03 | Iniziato | Goldman | Buy |
| 2021-05-25 | Iniziato | Wells Fargo | Equal Weight |
| 2021-01-28 | Iniziato | Truist | Buy |
| 2020-10-29 | Downgrade | UBS | Buy → Neutral |
| 2020-10-28 | Downgrade | Citigroup | Buy → Neutral |
| 2020-10-08 | Ripresa | BTIG Research | Buy |
| 2020-04-02 | Iniziato | Evercore ISI | Outperform |
| 2020-01-10 | Ripresa | BTIG Research | Buy |
| 2020-01-07 | Iniziato | Citigroup | Buy |
| 2019-12-13 | Iniziato | Dougherty & Company | Buy |
| 2019-11-15 | Iniziato | Stifel | Buy |
| 2019-10-17 | Reiterato | BofA/Merrill | Buy |
| 2019-10-01 | Ripresa | Craig Hallum | Buy |
| 2019-09-26 | Iniziato | Oppenheimer | Outperform |
| 2019-02-26 | Aggiornamento | Goldman | Neutral → Buy |
| 2018-10-09 | Iniziato | UBS | Buy |
| 2018-09-05 | Ripresa | The Benchmark Company | Hold |
| 2018-08-13 | Reiterato | Canaccord Genuity | Buy |
| 2018-04-03 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2018-01-29 | Iniziato | Goldman | Neutral |
| 2018-01-08 | Reiterato | The Benchmark Company | Buy |
| 2017-11-13 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2017-11-01 | Downgrade | BTIG Research | Buy → Neutral |
Mostra tutto
Exact Sciences Corp. Borsa (EXAS) Ultime notizie
Techne (TECH) Q3 Earnings and Revenues Beat Estimates
Zacks Investment Research
Edwards Lifesciences (EW) Q1 Earnings Top, 2024 Sales View Up
Zacks Investment Research
ICON (ICLR) Q1 Earnings Surpass Estimates, Margins Expand
Zacks Investment Research
Align Technology (ALGN) Q1 Earnings Top, 2024 Sales View Up
Zacks Investment Research
Labcorp (LH) Tops Q1 Earnings Estimates, Raises 2024 EPS View
Zacks Investment Research
Chemed (CHE) Lags Q1 Earnings Estimates, Reaffirms 2024 View
Zacks Investment Research
Exact Sciences Corp. Azioni (EXAS) Dati Finanziari
Exact Sciences Corp. (EXAS) Reddito 2024
EXAS ha riportato un ricavo (TTM) di $2.50 miliardi per il trimestre terminato il 2023-12-31, un +19.93% salita anno su anno.
Exact Sciences Corp. (EXAS) Reddito netto 2024
EXAS l'utile netto (TTM) è stato di -$204.15 milioni per il trimestre terminato il 2023-12-31, un +67.26% aumento anno su anno.
Exact Sciences Corp. (EXAS) Flusso di cassa 2024
EXAS ha registrato un flusso di cassa disponibile (TTM) di $31.93 milioni per il trimestre conclusosi con 2023-12-31, un +107.29% aumento anno su anno.
Exact Sciences Corp. (EXAS) Utile per azione 2024
L'utile per azione (TTM) di EXAS è stato pari a -$1.1357 per il trimestre terminato il 2023-12-31, un +67.92% crescita anno su anno.
Exact Sciences Corp. Azioni (EXAS) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Cunningham Everett | Chief Commercial Officer |
May 01 '24 |
Sale |
60.15 |
136 |
8,180 |
47,042 |
| Elliott Jeffrey Thomas | Chief Financial Officer |
May 01 '24 |
Sale |
60.15 |
136 |
8,180 |
11,795 |
| Baranick Brian | EVP, GM., Precision Oncology |
May 01 '24 |
Sale |
60.15 |
110 |
6,616 |
13,279 |
| ORVILLE JACOB A | General Manager, Screening |
May 01 '24 |
Sale |
60.15 |
102 |
6,135 |
14,440 |
| Condella Sarah | EVP, Human Resources |
May 01 '24 |
Sale |
60.15 |
102 |
6,135 |
72,611 |
| COWARD D SCOTT | Director |
May 01 '24 |
Sale |
60.15 |
67 |
4,030 |
44,644 |
| Herriott James | SVP, General Counsel & Sec |
May 01 '24 |
Sale |
60.15 |
30 |
1,804 |
9,866 |
| Baranick Brian | EVP, GM., Precision Oncology |
Apr 02 '24 |
Sale |
79.43 |
924 |
73,393 |
13,171 |
| Condella Sarah | EVP, Human Resources |
Apr 01 '24 |
Sale |
70.00 |
2,000 |
140,000 |
71,787 |
| Condella Sarah | EVP, Human Resources |
Mar 28 '24 |
Sale |
70.00 |
2,000 |
140,000 |
73,787 |
0.53%
4.89%
Capitalizzazione:
|
Volume (24 ore):